Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay

Kajal Biswas, Ranabir Das, Julie M. Eggington, Huanyu Qiao, Susan L. North, Stacey Stauffer, Sandra S. Burkett, Betty K. Martin, Eileen Southon, Scott C. Sizemore, Dmitry Pruss, Karla R. Bowles, Benjamin B. Roa, Neil Hunter, Lino Tessarollo, Richard J. Wenstrup, R. Andrew Byrd, Shyam K. Sharan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Single-nucleotide substitutions and small in-frame insertions or deletions identified in human breast cancer susceptibility genes BRCA1 and BRCA2 are frequently classified as variants of unknown clinical significance (VUS) due to the availability of very limited information about their functional consequences. Such variants can most reliably be classified as pathogenic or non-pathogenic based on the data of their co-segregation with breast cancer in affected families and/or their co-occurrence with a pathogenic mutation. Biological assays that examine the effect of variants on protein function can provide important information that can be used in conjunction with available familial data to determine the pathogenicity of VUS. In this report, we have used a previously described mouse embryonic stem (mES) cell-based functional assay to characterize eight BRCA2 VUS that affect highly conserved amino acid residues and map to the N-terminal PALB2-binding or the C-terminal DNA-binding domains. For several of these variants, very limited co-segregation information is available, making it difficult to determine their pathogenicity. Based on their ability to rescue the lethality of Brca2-deficient mES cells and their effect on sensitivity to DNA-damaging agents, homologous recombination and genomic integrity, we have classified these variants as pathogenic or non-pathogenic. In addition, we have used homology-based modeling as a predictive tool to assess the effect of some of these variants on the structural integrity of the C-terminal DNA-binding domain and also generated a knock-in mouse model to analyze the physiological significance of a residue reported to be essential for the interaction of BRCA2 with meiosis-specific recombinase, DMC1. Published by Oxford University Press 2012.

Original languageEnglish (US)
Article numberdds222
Pages (from-to)3993-4006
Number of pages14
JournalHuman Molecular Genetics
Volume21
Issue number18
DOIs
StatePublished - Sep 2012

Fingerprint

Virulence
DNA
Breast Neoplasms
Recombinases
Neoplasm Genes
Homologous Recombination
Meiosis
Biological Assay
Nucleotides
Amino Acids
Mutation
Proteins
Mouse Embryonic Stem Cells

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Biswas, K., Das, R., Eggington, J. M., Qiao, H., North, S. L., Stauffer, S., ... Sharan, S. K. (2012). Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay. Human Molecular Genetics, 21(18), 3993-4006. [dds222]. https://doi.org/10.1093/hmg/dds222

Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay. / Biswas, Kajal; Das, Ranabir; Eggington, Julie M.; Qiao, Huanyu; North, Susan L.; Stauffer, Stacey; Burkett, Sandra S.; Martin, Betty K.; Southon, Eileen; Sizemore, Scott C.; Pruss, Dmitry; Bowles, Karla R.; Roa, Benjamin B.; Hunter, Neil; Tessarollo, Lino; Wenstrup, Richard J.; Byrd, R. Andrew; Sharan, Shyam K.

In: Human Molecular Genetics, Vol. 21, No. 18, dds222, 09.2012, p. 3993-4006.

Research output: Contribution to journalArticle

Biswas, K, Das, R, Eggington, JM, Qiao, H, North, SL, Stauffer, S, Burkett, SS, Martin, BK, Southon, E, Sizemore, SC, Pruss, D, Bowles, KR, Roa, BB, Hunter, N, Tessarollo, L, Wenstrup, RJ, Byrd, RA & Sharan, SK 2012, 'Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay', Human Molecular Genetics, vol. 21, no. 18, dds222, pp. 3993-4006. https://doi.org/10.1093/hmg/dds222
Biswas, Kajal ; Das, Ranabir ; Eggington, Julie M. ; Qiao, Huanyu ; North, Susan L. ; Stauffer, Stacey ; Burkett, Sandra S. ; Martin, Betty K. ; Southon, Eileen ; Sizemore, Scott C. ; Pruss, Dmitry ; Bowles, Karla R. ; Roa, Benjamin B. ; Hunter, Neil ; Tessarollo, Lino ; Wenstrup, Richard J. ; Byrd, R. Andrew ; Sharan, Shyam K. / Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay. In: Human Molecular Genetics. 2012 ; Vol. 21, No. 18. pp. 3993-4006.
@article{9f436f037f424847a8c589208b95fac7,
title = "Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay",
abstract = "Single-nucleotide substitutions and small in-frame insertions or deletions identified in human breast cancer susceptibility genes BRCA1 and BRCA2 are frequently classified as variants of unknown clinical significance (VUS) due to the availability of very limited information about their functional consequences. Such variants can most reliably be classified as pathogenic or non-pathogenic based on the data of their co-segregation with breast cancer in affected families and/or their co-occurrence with a pathogenic mutation. Biological assays that examine the effect of variants on protein function can provide important information that can be used in conjunction with available familial data to determine the pathogenicity of VUS. In this report, we have used a previously described mouse embryonic stem (mES) cell-based functional assay to characterize eight BRCA2 VUS that affect highly conserved amino acid residues and map to the N-terminal PALB2-binding or the C-terminal DNA-binding domains. For several of these variants, very limited co-segregation information is available, making it difficult to determine their pathogenicity. Based on their ability to rescue the lethality of Brca2-deficient mES cells and their effect on sensitivity to DNA-damaging agents, homologous recombination and genomic integrity, we have classified these variants as pathogenic or non-pathogenic. In addition, we have used homology-based modeling as a predictive tool to assess the effect of some of these variants on the structural integrity of the C-terminal DNA-binding domain and also generated a knock-in mouse model to analyze the physiological significance of a residue reported to be essential for the interaction of BRCA2 with meiosis-specific recombinase, DMC1. Published by Oxford University Press 2012.",
author = "Kajal Biswas and Ranabir Das and Eggington, {Julie M.} and Huanyu Qiao and North, {Susan L.} and Stacey Stauffer and Burkett, {Sandra S.} and Martin, {Betty K.} and Eileen Southon and Sizemore, {Scott C.} and Dmitry Pruss and Bowles, {Karla R.} and Roa, {Benjamin B.} and Neil Hunter and Lino Tessarollo and Wenstrup, {Richard J.} and Byrd, {R. Andrew} and Sharan, {Shyam K.}",
year = "2012",
month = "9",
doi = "10.1093/hmg/dds222",
language = "English (US)",
volume = "21",
pages = "3993--4006",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Functional evaluation of BRCA2 variants mapping to the PALB2-binding and c-terminal dna-binding domains using a mouse es cell-based assay

AU - Biswas, Kajal

AU - Das, Ranabir

AU - Eggington, Julie M.

AU - Qiao, Huanyu

AU - North, Susan L.

AU - Stauffer, Stacey

AU - Burkett, Sandra S.

AU - Martin, Betty K.

AU - Southon, Eileen

AU - Sizemore, Scott C.

AU - Pruss, Dmitry

AU - Bowles, Karla R.

AU - Roa, Benjamin B.

AU - Hunter, Neil

AU - Tessarollo, Lino

AU - Wenstrup, Richard J.

AU - Byrd, R. Andrew

AU - Sharan, Shyam K.

PY - 2012/9

Y1 - 2012/9

N2 - Single-nucleotide substitutions and small in-frame insertions or deletions identified in human breast cancer susceptibility genes BRCA1 and BRCA2 are frequently classified as variants of unknown clinical significance (VUS) due to the availability of very limited information about their functional consequences. Such variants can most reliably be classified as pathogenic or non-pathogenic based on the data of their co-segregation with breast cancer in affected families and/or their co-occurrence with a pathogenic mutation. Biological assays that examine the effect of variants on protein function can provide important information that can be used in conjunction with available familial data to determine the pathogenicity of VUS. In this report, we have used a previously described mouse embryonic stem (mES) cell-based functional assay to characterize eight BRCA2 VUS that affect highly conserved amino acid residues and map to the N-terminal PALB2-binding or the C-terminal DNA-binding domains. For several of these variants, very limited co-segregation information is available, making it difficult to determine their pathogenicity. Based on their ability to rescue the lethality of Brca2-deficient mES cells and their effect on sensitivity to DNA-damaging agents, homologous recombination and genomic integrity, we have classified these variants as pathogenic or non-pathogenic. In addition, we have used homology-based modeling as a predictive tool to assess the effect of some of these variants on the structural integrity of the C-terminal DNA-binding domain and also generated a knock-in mouse model to analyze the physiological significance of a residue reported to be essential for the interaction of BRCA2 with meiosis-specific recombinase, DMC1. Published by Oxford University Press 2012.

AB - Single-nucleotide substitutions and small in-frame insertions or deletions identified in human breast cancer susceptibility genes BRCA1 and BRCA2 are frequently classified as variants of unknown clinical significance (VUS) due to the availability of very limited information about their functional consequences. Such variants can most reliably be classified as pathogenic or non-pathogenic based on the data of their co-segregation with breast cancer in affected families and/or their co-occurrence with a pathogenic mutation. Biological assays that examine the effect of variants on protein function can provide important information that can be used in conjunction with available familial data to determine the pathogenicity of VUS. In this report, we have used a previously described mouse embryonic stem (mES) cell-based functional assay to characterize eight BRCA2 VUS that affect highly conserved amino acid residues and map to the N-terminal PALB2-binding or the C-terminal DNA-binding domains. For several of these variants, very limited co-segregation information is available, making it difficult to determine their pathogenicity. Based on their ability to rescue the lethality of Brca2-deficient mES cells and their effect on sensitivity to DNA-damaging agents, homologous recombination and genomic integrity, we have classified these variants as pathogenic or non-pathogenic. In addition, we have used homology-based modeling as a predictive tool to assess the effect of some of these variants on the structural integrity of the C-terminal DNA-binding domain and also generated a knock-in mouse model to analyze the physiological significance of a residue reported to be essential for the interaction of BRCA2 with meiosis-specific recombinase, DMC1. Published by Oxford University Press 2012.

UR - http://www.scopus.com/inward/record.url?scp=84865749423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865749423&partnerID=8YFLogxK

U2 - 10.1093/hmg/dds222

DO - 10.1093/hmg/dds222

M3 - Article

VL - 21

SP - 3993

EP - 4006

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 18

M1 - dds222

ER -